Involuntary movements caused by tardive dyskinesia (TD), a movement disorder induced by dopamine-receptor antagonists like ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a chronic movement disorder impacting one in four people who take certain ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaignTD is a chronic movement disorder impacting one in four people who take certain pr ...

Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD, PhD, of the ...

Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.

Neurocrine BiosciencesNBIX shares rose late Tuesday after its bread-and-butter drug, Ingrezza, beat third-quarter ...

Neurocrine Biosciences (NASDAQ: NBIX) delivered a decisive earnings beat in Q3, posting adjusted EPS of $2.17 against ...

Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...

Doctors are suddenly warning against a cheap 'autism drug' being fast-tracked to ease certain symptoms of the condition.

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Good day, everyone, and welcome to today's Neurocrine Biosciences Third Quarter 2025 Results Call.

Stanford Medicine researchers found that a smartphone could monitor patients with two types of muscular dystrophy as well as ...